Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNorketamine hydrochloride
说明： Potent non-competitive NMDA antagonist; antinociceptive
化学名： 2-Amino-2-(2-chlorophenyl)cyclohexanone hydrochloride
纯度： ≥99% (HPLC)
生物活性 for Norketamine hydrochloride
Norketamine hydrochloride is a major metabolite of ketamine that is a potent non-competitive NMDA receptor antagonist (Ki = 3.6 μM for displacement of [3H]-MK 801 in rat brain). Antinociceptive and anesthetic in vivo.
R-enantiomer and S-enantiomer also available.
许可信息
Sold for research purposes under agreement from Pfizer Inc.
技术数据 for Norketamine hydrochloride
| 分子量 | 260.16 |
| 公式 | C12H14ClNO.HCl |
| 储存 | Desiccate at RT |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 79499-59-5 |
| PubChem ID | 25195026 |
| InChI Key | CLPOJGPBUGCUKT-UHFFFAOYSA-N |
| Smiles | Cl.NC1(CCCCC1=O)C1=C(Cl)C=CC=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for Norketamine hydrochloride
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| water | 26.02 | 100 |
制备储备液 for Norketamine hydrochloride
以下数据基于产品分子量 260.16。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.84 mL | 19.22 mL | 38.44 mL |
| 5 mM | 0.77 mL | 3.84 mL | 7.69 mL |
| 10 mM | 0.38 mL | 1.92 mL | 3.84 mL |
| 50 mM | 0.08 mL | 0.38 mL | 0.77 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for Norketamine hydrochloride
参考文献 for Norketamine hydrochloride
参考文献是支持产品生物活性的出版物。
Leung et al (1986) Comparative pharmacology in the rat of KA and its two principal metabolites, norKA and (Z)-6-hydroxynorKA. J.Med.Chem. 29 2396 PMID: 3783598
Ebert et al (1997) NorKA, the main metabolite of KA, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur.J.Pharmacol. 333 99 PMID: 9311667
Shimoyama et al (1999) Oral KA is antinociceptive in the rat formalin test: role of the metabolite, norKA. Pain 81 85 PMID: 10353496
If you know of a relevant reference for Norketamine hydrochloride, please let us know.
关键词: Norketamine hydrochloride, Norketamine hydrochloride supplier, Potent, non-competitive, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, Pfizer, Ketamine, and, Metabolites, 1970, Tocris Bioscience
篇 Norketamine hydrochloride 的引用文献
引用文献是使用了 Tocris 产品的出版物。
目前没有 Norketamine hydrochloride 的引用文献。 您是否知道使用了 Tocris Norketamine hydrochloride 的优秀论文？ 请告知我们.
Norketamine hydrochloride 的评论
目前没有该产品的评论。 Be the first to review Norketamine hydrochloride and earn rewards!
Have you used Norketamine hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.